| Literature DB >> 27277082 |
Chun-Hao Tsai1,2,3, Chih-Hsin Muo4, Chih-Hung Hung5, Tsung-Li Lin1, Ta-Ii Wang1, Yi-Chin Fong1,6,7, Horng-Chaung Hsu8,9,10.
Abstract
BACKGROUND: The choice of primary hip hemiarthroplasty or total hip arthroplasty for displaced femoral neck fracture is still controversial. Revision hip arthroplasty not only increases risk and cost but also could result in worse outcome. Determining the risk factors for revision can help inform medical decision-making and aid in risk stratification of publicly reported outcomes. Therefore, we conducted a nationwide population-based study to identify the disease-related risk factors and construct a risk score nomogram to predict revision surgery.Entities:
Mesh:
Year: 2016 PMID: 27277082 PMCID: PMC4897902 DOI: 10.1186/s13018-016-0400-3
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Incidence and hazard ratio for revision hip replacement and associated risk factor
|
| (%) | Event no. | PY | Ratea | Crude HR (95 % CI) | Adjusted HR (95 % CI) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | 68,030 | 1114 | 238,875 | 4.66 | ||||||
| Age, year | ||||||||||
| 20–29 | 53 | (0.08) | 9 | 260 | 34.57 | 30.9 (13.4–71.5)*** | 23.6 (10.2–54.7)*** | |||
| 30–39 | 158 | (0.23) | 11 | 832 | 13.23 | 12.0 (5.43–26.4)*** | 8.52 (3.85–18.9)*** | |||
| 40–49 | 499 | (0.73) | 25 | 2302 | 10.86 | 9.49 (4.93–18.3)*** | 6.90 (3.56–13.4)*** | |||
| 50–59 | 1862 | (2.74) | 63 | 7908 | 7.97 | 6.65–3.73 (11.9)*** | 5.48 (3.06–9.82)*** | |||
| 60–69 | 10,492 | (15.4) | 257 | 45,526 | 5.65 | 4.77 (2.79–8.17)*** | 4.35 (2.54–7.46)*** | |||
| 70–79 | 26,868 | (39.5) | 458 | 101,757 | 4.50 | 3.59 (2.11–6.12)*** | 3.38 (1.99–5.76)*** | |||
| 80–89 | 24,095 | (35.4) | 277 | 71,159 | 3.89 | 2.80 (1.64–4.80)*** | 2.73 (1.60–4.68)*** | |||
| ≥90 | 4003 | (5.88) | 14 | 9132 | 1.53 | 1.00 | 1.00 | |||
| Mean (SD) | 77.3 | (9.26) | ||||||||
| Gender | ||||||||||
| Women | 44,241 | (65.0) | 614 | 163,685 | 3.75 | 1.00 | 1.00 | |||
| Men | 23,789 | (35.0) | 500 | 75,190 | 6.65 | 1.69 (1.50–1.90)*** | 1.58 (1.40-1.78)*** | |||
| Comorbidity | ||||||||||
| Diabetes | ||||||||||
| No | 51,877 | (76.3) | 861 | 191,518 | 4.50 | 1.00 | ||||
| Yes | 16,153 | (23.7) | 253 | 47,357 | 5.34 | 1.09 (0.95–1.26) | ||||
| Osteoporosis | ||||||||||
| No | 64,702 | (95.1) | 1057 | 228,211 | 4.63 | 1.00 | ||||
| Yes | 3328 | (4.89) | 57 | 10,664 | 5.35 | 1.11 (0.85–1.45) | ||||
| RA | ||||||||||
| No | 67,472 | (99.2) | 1099 | 236,796 | 4.64 | 1.00 | ||||
| Yes | 558 | (0.82) | 15 | 2079 | 7.21 | 1.57 (0.94–2.61) | ||||
| Cancer | ||||||||||
| No | 62,848 | (92.4) | 1038 | 226,145 | 4.59 | 1.00 | ||||
| Yes | 5182 | (7.62) | 76 | 12,730 | 5.97 | 1.14 (0.90–1.44) | ||||
| COPD | ||||||||||
| No | 60,853 | (89.4) | 1008 | 219,410 | 4.59 | 1.00 | ||||
| Yes | 7177 | (10.6) | 106 | 19,465 | 5.45 | 1.07 (0.88–1.31) | ||||
| ESRD | ||||||||||
| No | 66,073 | (97.1) | 1068 | 234,698 | 4.55 | 1.00 | 1.00 | |||
| Yes | 1957 | (2.88) | 46 | 4177 | 11.01 | 1.99 (1.48–2.68)*** | 1.74 (1.29–2.34)*** | |||
| SLE | ||||||||||
| No | 67,963 | (99.9) | 1112 | 238,679 | 4.66 | 1.00 | ||||
| Yes | 67 | (0.10) | 2 | 196 | 10.19 | 2.03 (0.51–8.14) | ||||
| Ankylosing spondylitis | ||||||||||
| No | 64,346 | (94.6) | 1059 | 228,091 | 4.64 | 1.00 | ||||
| Yes | 3684 | (5.42) | 55 | 10,785 | 5.10 | 1.02 (0.78–1.34) | ||||
| Extrinsic asthma | ||||||||||
| No | 67,850 | (99.7) | 1112 | 238,299 | 4.67 | 1.00 | ||||
| Yes | 180 | (0.26) | 2 | 576 | 3.47 | 0.72 (0.18–2.89) | ||||
| HIV | ||||||||||
| No | 68,022 | (99.9) | 1114 | 238,853 | 4.66 | 1.00 | ||||
| Yes | 8 | (0.01) | 0 | 22 | 0.00 | –– | ||||
| Atherosclerosis | ||||||||||
| No | 67,550 | (99.3) | 1106 | 237,521 | 4.66 | 1.00 | ||||
| Yes | 480 | (0.71) | 8 | 1355 | 5.91 | 1.17 (0.58–2.35) | ||||
| Psoriasis | ||||||||||
| No | 67,898 | (99.8) | 1112 | 238,505 | 4.66 | 1.00 | ||||
| Yes | 132 | (0.19) | 2 | 370 | 5.40 | 1.09 (0.27–4.36) | ||||
| Viral hepatitis | ||||||||||
| No | 66,212 | (97.3) | 1080 | 234,523 | 4.61 | 1.00 | 1.00 | |||
| Yes | 1818 | (2.67) | 34 | 4353 | 7.81 | 1.46 (1.04–2.06)* | 1.30 (0.92–1.83) | |||
| Depression | ||||||||||
| No | 66,091 | (97.2) | 1081 | 232,874 | 4.64 | 1.00 | ||||
| Yes | 1939 | (2.85) | 33 | 6002 | 5.50 | 1.12 (0.79–1.59) | ||||
| Schizophrenia | ||||||||||
| No | 67,399 | (99.1) | 1088 | 236,468 | 4.60 | 1.00 | 1.00 | |||
| Yes | 631 | (0.93) | 26 | 2408 | 10.80 | 2.43 (1.65–3.58)*** | 1.88 (1.26–2.79)** | |||
| Heart failure | ||||||||||
| No | 62,500 | (91.9) | 1035 | 22,478 | 4.59 | 1.00 | ||||
| Yes | 5530 | (8.13) | 79 | 13,397 | 5.90 | 1.11 (0.89–1.40) | ||||
| UTI | ||||||||||
| No | 55,877 | (82.1) | 936 | 204,007 | 4.59 | 1.00 | ||||
| Yes | 12,153 | (17.9) | 178 | 34,869 | 5.10 | 1.2 (0.87–1.19) | ||||
| Ischemic heart disease | ||||||||||
| No | 55,681 | (81.9) | 915 | 203,038 | 4.51 | 1.00 | ||||
| Yes | 12,349 | (81.9) | 199 | 35,837 | 5.55 | 1.13 (0.97–1.32) | ||||
| Dementia | ||||||||||
| No | 65,633 | (96.5) | 1091 | 231,906 | 4.70 | 1.00 | 1.00 | |||
| Yes | 2397 | (3.52) | 23 | 6969 | 3.30 | 0.65 (0.43–0.98)* | 0.71 (0.47–1.07) | |||
PY person-years, HR hazard ratio, CI confidence interval, SD standard deviation, RA rheumatoid arthritis, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, SLE systemic lupus erythematosus, HIV human immunodeficiency virus, UTI urinary tract infection
*p < 0.05; **p < 0.01; ***p < 0.001
aPer 1000 person-years
Distribution of predictor between derivation and validation cohort
| Derivation cohort | Validation cohort | ||||
|---|---|---|---|---|---|
|
|
| ||||
|
| % |
| % | Chi-square | |
| Age, year | 0.98 | ||||
| 20–29 | 40 | 0.08 | 13 | 0.08 | |
| 30–39 | 113 | 0.22 | 45 | 0.26 | |
| 40–49 | 371 | 0.73 | 128 | 0.75 | |
| 50–59 | 1388 | 2.72 | 474 | 2.79 | |
| 60–69 | 7878 | 15.4 | 2614 | 15.4 | |
| 70–79 | 20,177 | 39.6 | 6691 | 39.3 | |
| 80–89 | 18,047 | 35.4 | 6048 | 35.6 | |
| ≥ 90 | 3007 | 5.89 | 996 | 5.86 | |
| Gender | 0.97 | ||||
| Women | 33,182 | 65.0 | 11,059 | 65.0 | |
| Men | 17,839 | 35.0 | 5959 | 35.0 | |
| Comorbidity | |||||
| ESRD | 1493 | 2.93 | 464 | 2.73 | 0.18 |
| Schizophrenia | 455 | 0.89 | 176 | 1.03 | 0.09 |
ESRD end-stage renal disease
Incidence and hazard ratio for revision hip replacement and associated risk factor in derivation cohort
| HR (95 % CI) | Regression coefficient |
| Risk score | |
|---|---|---|---|---|
| Age, year | ||||
| 20–29 | 40.4 (16.0–10.2) | 3.700 | < 0.0001 | 7 |
| 30–39 | 12.3 (4.85–31.0) | 2.506 | < 0.0001 | 6 |
| 40–49 | 8.40 (3.76–18.8) | 2.128 | < 0.0001 | 5 |
| 50–59 | 6.44 (3.14–12.2) | 1.862 | < 0.0001 | 4 |
| 60–69 | 4.92 (2.52–9.62) | 1.593 | < 0.0001 | 3 |
| 70–79 | 3.97 (2.05–7.71) | 1.380 | < 0.0001 | 2 |
| 80–89 | 3.38 (1.74–6.59) | 1.218 | 0.0003 | 1 |
| ≥ 90 | Ref. | 0 | 0 | |
| Gender | ||||
| Women | Ref. | 0 | 0 | |
| Men | 1.57 (1.36–1.80) | 0.449 | < 0.0001 | 2 |
| ESRD | ||||
| No | Ref. | 0 | 0 | |
| Yes | 1.72 (1.22–2.43) | 0.542 | 0.002 | 2 |
| Schizophrenia | ||||
| No | Ref. | 0 | 0 | |
| Yes | 1.84 (1.15–2.96) | 0.611 | 0.01 | 2 |
| Baseline disease–free probability | ||||
| At 10 years | 96.89 | |||
| AUROC % (95 % CI) | 61.9 (60.0–63.4) | |||
HR hazard ratio, CI confidence interval, AUROC the area under the receiver operating characteristic curve
Fig. 1Nomograms for the prediction of the RHA risk
Fig. 2Cumulative incidence for revision hip replacement among different risk score groups: low (risk score 0–2), median (risk score 3–4), and high (risk score 5+) in derivation (a) and validation (b) cohort
Top ten reasons due to revision hip replacement (N = 1114)
| Disease (ICD-9-CM) | Percentage |
|---|---|
| Mechanical complication of internal orthopedic device, implant, and graft (996.4) | 62.6 |
| Infection and inflammatory reaction due to internal prosthetic device, implant, and graft (996.6) | 8.71 |
| Other complications of internal (biological) (synthetic) prosthetic device, implant, and graft (996.7) | 3.50 |
| Shaft or unspecified part, closed (821.0) | 2.69 |
| Acquired deformities of hip (736.3) | 2.60 |
| Peritrochanteric fracture, closed (820.2) | 2.60 |
| Unspecified part of neck of femur, closed (820.8) | 2.42 |
| Osteoarthrosis, localized, not specified whether primary or secondary (715.3) | 1.97 |
| Pyogenic arthritis (711.0) | 1.53 |
| Mechanical complication of other specified prosthetic device, implant, and graft (996.5) | 1.44 |